Forest Teams Up With Microbia On IBS-C Agent Linaclotide
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms plan to initiate Phase III studies in the second half of 2008.
You may also be interested in...
Ironwood Poised To Move Linaclotide To Phase III In IBS-C
Partnered in the U.S. with Forest, firm formerly known as Microbia seeks to join Amitiza in space vacated by Zelnorm.
Ironwood Poised To Move Linaclotide To Phase III In IBS-C
Partnered in the U.S. with Forest, firm formerly known as Microbia seeks to join Amitiza in space vacated by Zelnorm.
Forest’s Linaclotide, Aclidinium Ready For Phase III
Drugs for constipation and COPD could require extra marketing effort, analysts say.